NYSE - Nasdaq Real Time Price • USD
Pfizer Inc. (PFE)
As of 3:08 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
58,496,000.00
58,496,000.00
100,330,000.00
81,288,000.00
41,651,000.00
Cost of Revenue
24,954,000.00
24,954,000.00
34,344,000.00
30,821,000.00
8,484,000.00
Gross Profit
33,542,000.00
33,542,000.00
65,986,000.00
50,467,000.00
33,167,000.00
Operating Expense
30,183,000.00
30,183,000.00
28,714,000.00
26,763,000.00
24,338,000.00
Operating Income
3,359,000.00
3,359,000.00
37,272,000.00
23,704,000.00
8,829,000.00
Net Non Operating Interest Income Expense
-585,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
Other Income Expense
-1,716,000.00
-1,716,000.00
-1,556,000.00
1,763,000.00
-415,000.00
Pretax Income
1,058,000.00
1,058,000.00
34,729,000.00
24,311,000.00
7,036,000.00
Tax Provision
-1,115,000.00
-1,115,000.00
3,328,000.00
1,852,000.00
370,000.00
Net Income Common Stockholders
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Diluted NI Available to Com Stockholders
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Basic EPS
0.38
--
5.59
3.92
1.73
Diluted EPS
0.37
--
5.47
3.85
1.71
Basic Average Shares
5,643,000.00
--
5,608,000.00
5,601,000.00
5,555,000.00
Diluted Average Shares
5,643,000.00
--
5,733,000.00
5,708,000.00
5,632,000.00
Total Expenses
55,137,000.00
55,137,000.00
63,058,000.00
57,584,000.00
32,822,000.00
Net Income from Continuing & Discontinued Operation
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Normalized Income
5,997,890.00
5,997,890.00
35,039,856.00
24,999,276.00
8,205,548.32
Interest Income
1,624,000.00
1,624,000.00
251,000.00
36,000.00
73,000.00
Interest Expense
2,209,000.00
2,209,000.00
1,238,000.00
1,291,000.00
1,449,000.00
Net Interest Income
-585,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
EBIT
3,267,000.00
3,267,000.00
35,967,000.00
25,602,000.00
8,485,000.00
EBITDA
8,000,000.00
9,557,000.00
41,031,000.00
30,793,000.00
13,262,000.00
Reconciled Cost of Revenue
24,954,000.00
23,397,000.00
32,889,000.00
29,330,000.00
7,055,000.00
Reconciled Depreciation
4,733,000.00
6,290,000.00
5,064,000.00
5,191,000.00
4,777,000.00
Net Income from Continuing Operation Net Minority Interest
2,134,000.00
2,134,000.00
31,366,000.00
22,413,000.00
6,630,000.00
Total Unusual Items Excluding Goodwill
-4,891,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Total Unusual Items
-4,891,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Normalized EBITDA
12,891,000.00
14,448,000.00
45,095,000.00
33,592,000.00
14,925,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,027,110.00
-1,027,110.00
-390,144.00
-212,724.00
-87,451.68
12/31/2020 - 6/1/1972
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
JNJ Johnson & Johnson
147.05
-1.00%
BMY Bristol-Myers Squibb Company
44.68
-8.56%
MRK Merck & Co., Inc.
130.48
+2.74%
LLY Eli Lilly and Company
724.89
-1.00%
ABBV AbbVie Inc.
166.91
-0.53%
GILD Gilead Sciences, Inc.
65.32
-2.62%
BIIB Biogen Inc.
202.34
+0.17%
AMGN Amgen Inc.
269.94
-1.12%
AZN AstraZeneca PLC
75.23
+5.65%
GSK GSK plc
40.92
+0.13%